136 related articles for article (PubMed ID: 21158732)
1. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
3. Insights from Pim1 structure for anti-cancer drug design.
Ogawa N; Yuki H; Tanaka A
Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
[TBL] [Abstract][Full Text] [Related]
4. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
5. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
7. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
8. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
9. Identification of quinones as novel PIM1 kinase inhibitors.
Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
11. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
12. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
13. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
[TBL] [Abstract][Full Text] [Related]
15. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
17. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.
An N; Lin YW; Mahajan S; Kellner JN; Wang Y; Li Z; Kraft AS; Kang Y
Stem Cells; 2013 Jun; 31(6):1202-12. PubMed ID: 23495171
[TBL] [Abstract][Full Text] [Related]
18. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
19. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]